Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study.
Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study.
复制标题
DOI：
10.1371/journal.pone.0054941
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Pei X
中科院分区：
文献类型：
--
作者：
Xi J;Zhu H;Liu D;Nan X;Zheng W;Liu K;Shi W;Chen L;Lv Y;Yan F;Li Y;Xie X;Wang Y;Yue W;Xu X;Wei X;Zhu J;Huang X;Pei X
目前，血小板供应的持续短缺已成为一个重要的医学和社会挑战，特别是在发展中国家，从脐带血中体外生产巨核细胞祖细胞（MP）可能是一种有效的血小板替代品。在本研究中，我们的目的是确定离体产生的MP在患者中的安全性和可行性。MPs的产生和特征在于从脐带血单核细胞在无血清培养基与细胞因子。我们研究了24例晚期恶性血液病患者的脐带血衍生MP扩增和输注的可行性。主要终点是输注脐带血来源的MP的安全性和耐受性。在接受体外生成细胞的患者中，未观察到不良反应，这些细胞的浓度中位数高达5.45× 106个细胞/kg体重。随访1年，未发现输注MP的患者发生急、慢性GVHD，即使ABO血型和HLA分型均不匹配。这些患者的初步结果非常令人鼓舞。他们认为输注脐带血来源的MP治疗血小板减少症是安全可行的。 www.chictr.org ChiCTR-TCH-09000333。
Currently, a constant shortage in the supply of platelets has become an important medical and society challenge, especially in developing country, and the in vitro production of megakaryocytic progenitor cells (MPs) from cord blood could represent an effective platelet substitute. In the present study, our objective was to determine the safety and feasibility of ex vivo generated MPs in patients. MPs were produced and characterized from cord blood mononuclear cells under a serum free medium with cytokines. We investigated the feasibility of expansion and infusion of cord blood-derived MPs in 24 patients with advanced hematological malignancyes. The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. No adverse effects were observed in patients who received ex vivo-generated cells at concentrations of up to a median value of 5.45×106cells/kg of body weight. With one year follow-up, acute and chronic GVHD had not been observed among patients who received MPs infusion, even without ABO blood group and HLA typing matching. These initial results in patients are very encouraging. They suggest that infusion of cord blood-derived MPs appears safe and feasible for treatment of thrombocytopenia. www.chictr.org ChiCTR-TCH-09000333.
登录
查看更多内容
影响因子：
23.9
作者：
Mercher T;Cornejo MG;Sears C;Kindler T;Moore SA;Maillard I;Pear WS;Aster JC;Gilliland DG
通讯作者：
Gilliland DG
影响因子：
44.1
作者：
通讯作者：
--
影响因子：
20.3
作者：
Takayama, Naoya;Nishikii, Hidekazu;Nakauchi, Hirornitsu
通讯作者：
Nakauchi, Hirornitsu
影响因子：
2.6
作者：
Chen, Te-Wei;Hwang, Shiaw-Min;Yao, Chao-Ling
通讯作者：
Yao, Chao-Ling
影响因子：
1.8
作者：
Aghideh, Ali Noroozi;Kheirandish, Maryam;Gharehbaghian, Ahmad
通讯作者：
Gharehbaghian, Ahmad